|
Composition
|
Name
|
Composition
|
Institution
|
|
María Gemma Fernández Juárez
|
Jefe de Servicio de Nefrología
|
Hospital Universitario La Paz
|
|
María Auxiliadora Bajo Rubio
|
Jefe de Sección de Nefrología
Profesora Asociada. Facultad de Medicina
|
Hospital Universitario La Paz
Universidad Autónoma de Madrid
|
|
María José Castro Notario
|
Enfermera
|
Hospital Universitario La Paz
|
|
Olga Costero Fernández
|
Facultativo Especialista de Área en Nefrología
|
Hospital Universitario La Paz
|
|
Gloria del Peso Gilsanz
|
Facultativo Especialista de Área en Nefrología
|
Hospital Universitario La Paz
|
|
María Elena González García
|
Facultativo Especialista de Área en Nefrología
|
Hospital Universitario La Paz
|
|
Carlos Jiménez Martín
|
Jefe de Sección de Nefrología
|
Hospital Universitario La Paz
|
|
María Ovidia López Oliva
|
Facultativo Especialista de Área en Nefrología
|
Hospital Universitario La Paz
|
|
Almudena Pérez Torres
|
Dietista-Nutricionista
|
Hospital Universitario Santa Cristina
|
|
Begoña Rivas Becerra
|
Facultativo Especialista de Área en Nefrología
|
Hospital Universitario La Paz
|
|
Rafael Jesús Sánchez Villanueva
|
Facultativo Especialista de Área en Nefrología
|
Hospital Universitario La Paz
|
Strategic Objective
The strategic objective of this care-research group is toenable, by developing a deep understanding of the various components that make up nephrology (kidney diseases in initial stages, progression of kidney disease, particular and general complications of dialysis and kidney transplantation), access by affected patients to the best diagnostic and therapeutic interventions available at any time. Each of the areas must ensure a minimum level of research and development activity representing the innovation in these areas. The lines of research are at times cross-sectional to the four components indicated for nephrology.
Research Lines
The lines of research are occasionally cross-sectional to the four components indicated for nephrology as a whole.
A) Incipient nephropathies and kidney disease progression:
• Glomerular and tubular nephropathies. New diagnostic markers and interventions.
• Organisational Research (computerisation, organisation of generational change in the department and network).
• Morbidity, mortality and progression of Diabetic Nephropathy and other glomerular nephropathies.
• Autosomal Dominant Polycystic Kidney Disease. Family Studies and treatment approaches.
• Association of cardiovascular disease with the progress of nephropathies (NEFRONA multicenter study, REDinREN).
• Incorporation of a psychologist into the department of nephrology: criteria and process. Issues on monitoring therapeutic adherence.
• Occult Hepatits C virus in different kidney disease situations.
B) Complications of dialysis
• Establishment of normal peritoneal functional in humans. Implications for patient survival and long-term treatment. New dialysis fluids. Aquaporin 1 (AQP1) and its genetic polymorphisms: relationship with peritoneal transport of water. Multicentre European study.
• The alternatively activated macrophage in peritoneal effluent (AAM): its relationship with defence and peritoneal fibrosis. CCL18 as a chemokine of AAM and a mediator of peritoneal fibrosis.
• Peritoneal biopsy for the complete evaluation of the peritoneal membrane. A correspondence study with cell and components findings in peritoneal effluent during kidney transplantation (Multicenter).
• Cardiovascular risk in patients with advanced kidney disease and on dialysis. Endocrine aspects. The abdominal adipocyte and adipocytokines. FABP antagonists as blockers of the adipocyte-macrophage response. Non-thyroidal diseases, influence on CKD patients. FGF 21 role in uremic insulin resistance.
• Mouse model for peritoneal dialysis: exploration of the effects of dialysis fluids, pharmacological interventions and genetic manipulation (KO, transgenic).
• Allergic reactions to hemodialysis membranes: mechanisms and alternatives.
C) Complications of kidney transplantation:
• Toxicity due to immunosuppressants. Ultrasound contrast in the analysis of renal microvasculature in kidney transplantation and complications.
• The involvement of CMV in the renal graft response: anticipated diagnosis.
• Kidney graft response. Thymoglobulin administered to a cadaver donor: effects on the expression of HLA antigens by tubular cells (clinical trial).
• Post-transplant monitorization of anti-HLA antibodies. Local development.
• The transplantation career since the values of the patient: health outcome repercussion.
|